This patient-driven business model is overlaid with a securitization layer. AVEX.AI is a securitization pathway that allows traditional investors to invest in AVEX without participating in the utility market, thus separating the investment/speculative layer from the purely utility-based layer.
This hybrid model is to ensure that investors who want to invest in the performance of AVEX can do so through a tracker certificate offered on a Swiss ISIN, without confounding the simple patient access model. The AVEX offered on the tracker is classified as the underlying, vaulted by a Swiss institution as part of a structured product conforming to Swiss law.
This ingenious mode places innovations in the patients' hands and de-risks investor participation in life science innovation investment. It makes investing in blockchain-based assets easy because investors do not have to tackle issues of custody and security. It appeals to crypto funds and traditional funds alike, opening the gate to the trillion-dollar derivatives market.
THE NEW PATH TO PATIENT-DRIVEN TREATMENTS AND CURES
Aevolve is a protocol that supports medical innovations from R&D stages to full-scale commercialization, by connecting patients, investors, and scientific innovators.
INVESTOR ACCESS TO A BILLION-DOLLAR ECOSYSTEM
This new asset class provides exposure to opportunities in blockchain, free of the risks associated with previous token offerings. Coming soon to the the SIX Swiss Stock Exchange.
FOR PATIENTS AND INNOVATORS
This innovation marketplace connects patients and the global community directly with scientific innovators and experts from all over the world to address various stages of the innovation life cycle.
AVEX Token & The Aevolve Protocol
Cutting-edge medical science meets blockchain-driven technology to create new opportunities to drive innovation.